SIRT3 & SIRT7: Potential novel biomarkers for determining outcome in pancreatic cancer patients

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  McGlynn, Liane M ^a   McCluney, Simon ^a   Jamieson, Nigel B ^a,b   Thomson, Jackie ^a   MacDonald, Alasdair I ^a   Oien, Karin ^c   Dickson, Euan J ^b   Carter, C Ross ^b   McKay, Colin J ^b   Shiels, Paul G ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SIRTUIN 3; SIRTUIN 7; SIRT3 PROTEIN, HUMAN; SIRT7 PROTEIN, HUMAN; SIRTUIN; TUMOR MARKER;

AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PHENOTYPE; PROTEIN EXPRESSION; TISSUE MICROARRAY; ANTIBODY SPECIFICITY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ANTIBODY SPECIFICITY; BIOMARKERS, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; SIRTUIN 3; SIRTUINS; TREATMENT OUTCOME;

EID: 84938678715     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131344     Document Type: Article

References (54)

1. Cancer Research UK. Pancreatic Cancer Survival Statistics 2013 [updated 2013]. Available: http://info.cancerresearchuk.org/cancerstats/types/pancreas/survival/.
2. Keleg S, Buchler P, Ludwig R, Buchler MW, Friess H. Invasion and metastasis in pancreatic cancer. MolCancer. 2003; 2:14.
3. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011; 378 (9791):607-20. doi: S0140-6736(10)62307-0 [pii]; doi: 10.1016/S0140-6736(10)62307-0 PMID: 21620466
4. Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002; 94(10):2766-92. PMID: 12173348
5. Shiels PG. Improving precision in investigating aging: why telomeres can cause problems. JGerontolA BiolSciMedSci. 2010; 65(8):789-91. doi: glq095 [pii]; doi: 10.1093/gerona/glq095
6. Sebastian C, Zwaans BM, Silberman DM, Gymrek M, Goren A, Zhong L, et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell. 2012; 151(6):1185-99. doi: S0092-8674(12)01351-7 [pii]; doi: 10.1016/j.cell.2012.10.047 PMID: 23217706
7. McGlynn LM, Zino S, MacDonald AI, Curle J, Reilly JE, Mohammed ZM, et al. SIRT2: Tumour suppressor or tumour promoter in operable breast cancer? EurJCancer. 2013. doi: S0959-8049(13)00905-2 [pii]; doi: 10.1016/j.ejca.2013.10.005
8. F M, LM M, S Z, C M, P L, PG H, et al. Altered Sirtuin Expression is Implicated in the Pathogenesis of Colorectal Cancer. Cancer Research - submitted2012.
9. Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, George WD, et al. Altered sirtuin expression is associated with node-positive breast cancer. BrJCancer. 2006; 95(8):1056-61.
10. Gartenberg MR. The Sir proteins of Saccharomyces cerevisiae: mediators of transcriptional silencing and much more. CurrOpinMicrobiol. 2000; 3(2):132-7.
11. Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007; 26(37):5489-504. PMID: 17694089
12. Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell. 2006; 126(2):257-68. PMID: 16873059
13. McGuinness D, McGuinness DH, McCaul JA, Shiels PG. Sirtuins, bioageing, and cancer. JAging Res. 2011; 2011:235754. doi: 10.4061/2011/235754
14. Schumacker PT. A tumor suppressor SIRTainty. Cancer Cell. 2010; 17(1):5-6. doi: S1535-6108(09)00436-X [pii]; doi: 10.1016/j.ccr.2009.12.032 PMID: 20129243
15. Ford J, Jiang M, Milner J. Cancer-Specific Functions of SIRT1 Enable Human Epithelial Cancer Cell Growth and Survival. Cancer Research. 2005; 65(22):10457-63. PMID: 16288037
16. PG S, RW D. Ageing and Death in Neurons. The Molecular Biology of the Neurone. 2nd ed2003. p. 435-64.
17. Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005; 19(10):1751-9. PMID: 16121216
18. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007; 67(14):6612-8. doi: 67/14/6612 [pii]; doi: 10.1158/0008-5472.CAN-07-0085 PMID: 17638871
19. Stunkel W, Campbell RM. Sirtuin 1 (SIRT1): the misunderstood HDAC. JBiomolScreen. 2011; 16 (10):1153-69. doi: 1087057111422103 [pii]; doi: 10.1177/1087057111422103
20. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 2008; 14(4):312-23. doi: S1535-6108(08)00294-8 [pii]; doi: 10.1016/j.ccr.2008.09.001 PMID: 18835033
21. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoSGenet. 2006; 2(3):e40. doi: 10.1371/journal.pgen.0020040
22. Zhong L, Mostoslavsky R. SIRT6: a master epigenetic gatekeeper of glucose metabolism. Transcription. 2010; 1(1):17-21. doi: 10.4161/trns.1.1.12143 PMID: 21327158
23. Zhao G, Cui J, Zhang JG, Qin Q, Chen Q, Yin T, et al. SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. Gene Ther. 2011; 18(9):920-8. doi: 10.1038/gt.2011.81 PMID: 21677689
24. Wauters E, Sanchez-Arevalo Lobo VJ, Pinho AV, Mawson A, Herranz D, Wu J, et al. Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer cell viability in pancreatic cancer. Cancer Res. 2013; 73(7):2357-67. doi: 0008-5472.CAN-12-3359 [pii]; doi: 10.1158/0008-5472.CAN-12-3359 PMID: 23370328
25. Cho IR, Koh SS, Malilas W, Srisuttee R, Moon J, Choi YW, et al. SIRT1 inhibits proliferation of pancreatic cancer cells expressing pancreatic adenocarcinoma up-regulated factor (PAUF), a novel oncogene, by suppression of beta-catenin. BiochemBiophysResCommun. 2012; 423(2):270-5. doi: S0006-291X(12)00997-7 [pii]; doi: 10.1016/j.bbrc.2012.05.107
26. Bauer I, Grozio A, Lasiglie D, Basile G, Sturla L, Magnone M, et al. The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. JBiolChem. 2012; 287(49):40924-37. doi: M112.405837 [pii]; doi: 10.1074/jbc.M112.405837
27. Jamieson NB, Foulis AK, Oien KA, Going JJ, Glen P, Dickson EJ, et al. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. AnnSurg. 2010; 251(6):1003-10. doi: 10.1097/SLA.0b013e3181d77369
28. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. ProcNatlAcadSciUSA. 2010; 107(1):246-51. doi: 0908428107 [pii]; doi: 10.1073/pnas.0908428107
29. Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology. 2006; 48(7):787-94. PMID: 16722926
30. Alhazzazi TY, Kamarajan P, Verdin E, Kapila YL. SIRT3 and cancer: tumor promoter or suppressor? BiochimBiophysActa. 2011; 1816(1):80-8. doi: S0304-419X(11)00020-5 [pii]; doi: 10.1016/j.bbcan.2011.04.004
31. Li S, Banck M, Mujtaba S, Zhou MM, Sugrue MM, Walsh MJ. p53-induced growth arrest is regulated by the mitochondrial SirT3 deacetylase. PLoSOne. 2010; 5(5):e10486. doi: 10.1371/journal.pone.0010486
32. Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 2010; 12(6):662-7. doi: S1550-4131(10)00407-9 [pii]; doi: 10.1016/j.cmet.2010.11.015 PMID: 21109198
33. Allison SJ, Milner J. SIRT3 is Pro-Apoptotic and Participates in Distinct Basal Apoptotic Pathways. Cell Cycle. 2007; 6(21):2669-77. PMID: 17957139
34. Bell EL, Emerling BM, Ricoult SJ, Guarente L. SirT3 suppresses hypoxia inducible factor 1alpha and tumor growth by inhibiting mitochondrial ROS production. Oncogene. 2011; 30(26):2986-96. doi: onc201137 [pii]; doi: 10.1038/onc.2011.37 PMID: 21358671
35. Finley LW, Haigis MC. Metabolic regulation by SIRT3: implications for tumorigenesis. Trends MolMed. 2012; 18(9):516-23. doi: S1471-4914(12)00080-9 [pii]; doi: 10.1016/j.molmed.2012.05.004
36. Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J, et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell. 2011; 19(3):416-28. doi: S1535-6108(11)00085-7 [pii]; doi: 10.1016/j.ccr.2011.02.014 PMID: 21397863
37. Haigis MC, Deng CX, Finley LWS, Kim HS, Gius D. SIRT3 Is a Mitochondrial Tumor Suppressor: A Scientific Tale That Connects Aberrant Cellular ROS, the Warburg Effect, and Carcinogenesis. Cancer Research. 2012; 72(10):2468-72. doi: 10.1158/0008-5472.CAN-11-3633 PMID: 22589271
38. Lee C, Longo VD. Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene. 2011; 30(30):3305-16. doi: onc201191 [pii]; doi: 10.1038/onc.2011.91 PMID: 21516129
39. Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. SciTranslMed. 2012; 4(124):124ra27. doi: scitranslmed.3003293 [pii]; doi: 10.1126/scitranslmed.3003293
40. Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C, et al. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell. 2010; 143(5):802-12. doi: S0092-8674(10)01138-4 [pii]; doi: 10.1016/j.cell.2010.10.002 PMID: 21094524
41. Zhu Y, Yan Y, Gius DR, Vassilopoulos A. Metabolic regulation of Sirtuins upon fasting and the implication for cancer. CurrOpinOncol. 2013; 25(6):630-6. doi: 10.1097/01.cco.0000432527.49984.a3
42. Kelly GS. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2. AlternMedRev. 2010; 15(4):313-28.
43. Yamamoto H, Schoonjans K, Auwerx J. Sirtuin Functions in Health and Disease. Molecular Endocrinology. 2007; 21(8):1745-55. PMID: 17456799
44. Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev. 2006; 20(9):1075-80. PMID: 16618798
45. Vakhrusheva O, Braeuer D, Liu Z, Braun T, Bober E. Sirt7-dependent inhibition of cell growth and proliferation might be instrumental to mediate tissue integrity during aging. JPhysiol Pharmacol. 2008; 59 Suppl 9:201-12.
46. Vakhrusheva O, Smolka C, Gajawada P, Kostin S, Boettger T, Kubin T, et al. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. CircRes. 2008; 102(6):703-10. doi: CIRCRESAHA.107.164558 [pii]; doi: 10.1161/CIRCRESAHA.107.164558
47. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54(18):4855-78. PMID: 8069852
48. Barber MF, Michishita-Kioi E, Xi Y, Tasselli L, Kioi M, Moqtaderi Z, et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature. 2012; 487(7405):114-8. doi: nature11043 [pii]; doi: 10.1038/nature11043 PMID: 22722849
49. Martinez-Redondo P, Santos-Barriopedro I, Vaquero A. A big step for SIRT7, one giant leap for Sirtuins... in cancer. Cancer Cell. 2012; 21(6):719-21. doi: S1535-6108(12)00219-X [pii]; doi: 10.1016/j.ccr.2012.05.028 PMID: 22698398
50. Li L, Bhatia R. The controversial role of Sirtuins in tumorigenesis-SIRT7 joins the debate. Cell Res. 2013; 23(1):10-2. doi: cr2012112 [pii]; doi: 10.1038/cr.2012.112 PMID: 22847743
51. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, et al. Global levels of histone modifications predict prognosis in different cancers. AmJPathol. 2009; 174(5):1619-28. doi: S0002-9440(10)61020-6 [pii]; doi: 10.2353/ajpath.2009.080874
52. Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, Cheung-Lau G, et al. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. JClinOncol. 2010; 28(8):1358-65. doi: JCO.2009.24.5639 [pii]; doi: 10.1200/JCO.2009.24.5639
53. Frye R. "SIRT8" expressed in thyroid cancer is actually SIRT7. BrJCancer. 2002; 87(12):1479. doi: 10.1038/sj.bjc.6600635
54. De Nigris F, Cerutti J, Morelli C, Califano D, Chiariotti L, Viglietto G, et al. Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. BrJCancer. 2002; 87(12):1479.